Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic

Trial Details

NCT ID
NCT05559879
Phase
PHASE1 / PHASE2
Sponsor
University of Alabama at Birmingham
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Cabo + Dostarlimab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

  • Histologically confirmed diagnosis of carcinosarcoma (independent of organ of gynecologic origin)
  • Received at least one prior chemotherapy regimen for their cancer
  • Must have measurable or evaluable lesion defined by iRECIST
  • Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or sta…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →